BIOFILCHEM vs WANBURY: Stock Comparison

Biofil Chemicals & Pharmaceuticals Limited vs Wanbury Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Wanbury Ltd is the larger company by market capitalisation. Biofil Chemicals & Pharmaceuticals Limited shows faster revenue growth and lower leverage, while Wanbury Ltd shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and Wanbury Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOFILCHEM is more favourable on 3 of 11 scored metrics and WANBURY on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WANBURY is the larger company
₹1,091 Cr vs ₹53 Cr
EPS
WANBURY has higher earnings per share
₹13.1 vs ₹1.71
Revenue Growth (TTM YoY)
BIOFILCHEM has faster revenue growth
-9.3% vs -19.2%
EPS Growth (TTM YoY)
BIOFILCHEM has faster EPS growth
10.8% vs 0%
Qtr Sales Growth
WANBURY has stronger quarterly sales growth
24.5% vs -9.34%
Qtr Profit Growth
WANBURY has stronger quarterly profit growth
1,197% vs 5%
ROE
WANBURY has a higher ROE
76.5% vs 13.8%
ROCE
WANBURY has a higher ROCE
36.6% vs 15.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMWANBURY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMWANBURY
Live Price₹32.64₹312.45
Day Change-0.55%-5.1%
Volume4,0482.85 L
52-Week High₹46.34₹358.85
52-Week Low₹25.6₹161.5
Distance from 52W High-29.56%-12.93%

Valuation

MetricBIOFILCHEMWANBURY
Market Cap₹53 Cr₹1,091 Cr
P/E Ratio0x
P/B Ratio0x
EPS₹1.71₹13.1
Book Value₹13.21₹18.1
Dividend Yield0%0%

Growth

MetricBIOFILCHEMWANBURY
Revenue Growth (TTM YoY)-9.3%-19.2%
EPS Growth (TTM YoY)10.8%0%
Qtr Sales Growth-9.34%24.5%
Qtr Profit Growth5%1,197%

Profitability & Leverage

MetricBIOFILCHEMWANBURY
ROE13.8%76.5%
ROCE15.8%36.6%
Net Margin9.81%10.17%
Operating Margin2.29%14%
Debt to Equity0.14x3.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMWANBURY
Promoter Holding46.79%34.36%
FII Holding0%0.89% 0.3 pp
DII Holding0.08%0.06% 0.06 pp
Public Holding53.13%56.03% 0.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and Wanbury Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.